-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
• Adjusted EBITDA at least in line with last year
• Confirmation of full-year free cash flow forecast: approximately EUR 700 million
• Third-quarter sales and operating income were slightly lower than a year earlier
• Implement stricter cost controls to safeguard profitability
Evonik affirmed its full-year profit forecast despite continued weakness in the global econo.
"Earlier, we took stricter cost control and additional emergency measures to deal with the impact of the global economic downturn," said Evonik Chairman Cullm.
The cost reduction and efficiency increase plan launched by the company in 2018 has been further implement.
Evonik confirmed its full-year free cash flow forecast of around 700 million euros, a significant increase compared to last ye.
The global economic slowdown also affected Evonik's third-quarter resul.
Business segment performance
Business segment performanceResource Efficiency: Sales fell 1 percent to 4 billion eur.
Resource efficiency business segment:
Nutrition and Consumer Chemicals : Sales fell 2 percent to 14 billion eur.
Nutrition and Consumer Chemicals business segment
Functional Materials : Sales were down 20 percent year-on-year to EUR 475 milli.
Functional Materials Business Sector